Icu Medical Inc/de (ICUI): Virginia Ruth Sanzone , VP, General Counsel of Icu Medical Inc/de sold 1,903 shares on Sep 12, 2016. The Insider selling transaction was reported by the company on Sep 13, 2016 to the Securities and Exchange Commission. The shares were sold at $121.29 per share for a total value of $230,824.19 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 13, 2016, Scott E Lamb (Chief Financial Officer,) sold 28,526 shares at $121.90 per share price.On Aug 17, 2016, Kevin J Mcgrody (Controller) sold 14,257 shares at $124.46 per share price.Also, On Aug 12, 2016, Thomas D Mccall (Vice President and Gen’l Mgr.) sold 18,559 shares at $124.46 per share price.On Aug 9, 2016, Joseph R Saucedo (director) sold 8,000 shares at $125.00 per share price.
Shares of ICU Medical Incorporated (ICUI) ended Monday, Sep 12, 2016 session in red amid volatile trading. The shares closed down -0.13 points or -0.11% at $121.9 with 209,945 shares getting traded. Post opening the session at $121.08, the shares hit an intraday low of $120.66 and an intraday high of $123.86 and the price vacillated in this range throughout the day. The company has a market cap of $1,966 M and the number of outstanding shares has been calculated to be 16,132,041 shares. The 52-week high of ICU Medical Incorporated is $128.925 and the 52-week low is $85.56.
ICU Medical Inc. is engaged in the development manufacturing and sales of medical devices used in infusion therapy oncology and critical care applications. The Companys product line includes needlefree connection devices custom infusion sets closed system transfer devices (CSTD) for the handling of hazardous drugs advanced sensor catheters needlefree closed blood sampling systems disposable pressure transducer systems and innovative hemodynamic monitoring systems. The Companys products are used in acute care hospitals and ambulatory clinics in more than 60 countries worldwide. Its products are categorized into three market segments: Infusion Therapy Critical Care and Oncology. Its primary products include MicroClave and MicroClave Clear Anti-Microbial MicroClave Tego needlefree hemodialysis connector Transpac disposable pressure transducers Pulmonary artery thermodilution catheters ChemoLock CSTD and components and Diana hazardous drug compounding system among others.